探讨应用空白微球行TACE治疗肝癌临床疗效。

回顾性分析2016年1月至2018年6月在佛山市第一人民医院行TACE治疗的80例肝癌患者临床资料。患者均签署知情同意书，符合医学伦理学规定。其中男53例，女27例；年龄38～82岁，中位年龄56岁。根据治疗方法不同将患者分为空白微球组和对照组，每组40例。空白微球组采用空白微球+表柔比星，对照组采用传统的碘化油乳剂+表柔比星。两组近期疗效、肿瘤坏死率、不良反应发生率比较采用χ²检验。癌症生存质量评分比较采用t检验。

术后6个月空白微球组客观缓解率、肿瘤坏死率分别为83%（33/40）、85%（34/40），明显高于对照组的60%（24/40）、65%（26/40） （χ²=4.943，4.267；P<0.05）。术后6个月空白微球组生理健康、心理健康、社会功能、总体感觉评分分别为（87±8）、（86±8）、（87±8）、（87±8）分，明显高于对照组的（78±7）、（77±7）、（79±7）、（78±7）分（t=5.137，4.785，4.774，4.835；P<0.05）。空白微球组术后不良反应发生率5%（2/40），明显低于对照组的20%（8/40） （χ²=4.114，P<0.05）。

应用空白微球行TACE治疗肝癌可有效提高患者的近期疗效和肿瘤坏死率，并可降低术后不良反应发生率。

To explore the clinical efficacy of transarterial chemoembolization (TACE) with blank microspheres for liver cancer.

Clinical data of 80 patients with liver cancer who underwent TACE from January 2016 to June 2018 at the First People's Hospital of Foshan were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them, 53 patients were male and 27 female, aged 38-82 years with a median of 56 years. The patients were assigned to blank microsphere group and control group according to different treatments, with 40 cases in each group. Patients in blank microsphere group received treatments of blank microsphere + epirubicin and patients in control group received treatments of traditional lipiodol emulsion + epirubicin. Comparisons of short-term outcome, tumor necrosis rate and incidence of adverse reaction between two groups were performed using Chi-square test. Comparison of scores of life quality after cancer survivorship was conducted using t test.

The objective response rate and tumor necrosis rate at postoperative 6 months in blank microsphere group were 83%(33/40) and 85%(34/40), respectively, which were significantly higher than 60%(24/40) and 65%(26/40) in control group (χ²=4.943, 4.267; P<0.05). At postoperative 6 month, the scores of physical health, mental health, social functioning, and general well-being in blank microsphere group were 87±8, 86±8, 87±8 and 87±8 respectively, which were significantly higher than 78±7, 77±7, 79±7 and 78±7 in control group (t=5.137, 4.785, 4.774, 4.835; P<0.05). The incidence of postoperative adverse reactions was 5%(2/40) in blank microsphere group, which was significantly lower than 20%(8/40) in control group (χ²=4.114, P<0.05).

TACE with blank microsphere for liver cancer can elevate the short-term curative efficacy and tumor necrosis rate and decrease the incidence of postoperative adverse reactions.